Sharon X. Wen

Array ( [id] => 19018893 [patent_doc_number] => 20240075064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => COMPOSITIONS AND METHODS FOR EXPANSION OF T CELLS AND TUMOR INFILTRATING LYMPHOCYTES [patent_app_type] => utility [patent_app_number] => 18/261761 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020232 [patent_doc_number] => 20240076403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => HER2 ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/267561 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18352690 [patent_doc_number] => 20230140801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO 5' TO 3' EXONUCLEASE ACTIVE DOMAIN OF DNA POLYMERASE [patent_app_type] => utility [patent_app_number] => 17/996601 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988824 [patent_doc_number] => 20220354861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE [patent_app_type] => utility [patent_app_number] => 17/537786 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443816 [patent_doc_number] => 20220064321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTI-CD20 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/531011 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687770 [patent_doc_number] => 20220195062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => DOSING REGIMEN OF COMBINATION OF ANTICD20 AND ANTI-BLYS ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/519063 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546727 [patent_doc_number] => 20220118068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Modulation of Proprotein Convertase Subtilisin/Kexin 9 Expression (PCSK9) with HSP 27 and/or HSP25 [patent_app_type] => utility [patent_app_number] => 17/515001 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595396 [patent_doc_number] => 20220144969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => METHODS FOR REDUCING CARDIOVASCULAR RISK [patent_app_type] => utility [patent_app_number] => 17/504921 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642011 [patent_doc_number] => 20220169749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK [patent_app_type] => utility [patent_app_number] => 17/500214 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21059 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473984 [patent_doc_number] => 20220081488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB [patent_app_type] => utility [patent_app_number] => 17/495559 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368331 [patent_doc_number] => 20220023383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS [patent_app_type] => utility [patent_app_number] => 17/493896 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672716 [patent_doc_number] => 20220185883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 [patent_app_type] => utility [patent_app_number] => 17/484794 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739619 [patent_doc_number] => 20230348578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/021912 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964213 [patent_doc_number] => 11897964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Anti-PSGL-1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/460883 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 21264 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265390 [patent_doc_number] => 20240209089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => CD8 BINDING POLYPEPTIDE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/017236 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20336550 [patent_doc_number] => 20250340670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO PTK7 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/016100 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18157953 [patent_doc_number] => 20230024543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => METHODS OF TREATING ANAEMIA [patent_app_type] => utility [patent_app_number] => 17/370446 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 220629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17370446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656079 [patent_doc_number] => 20230301950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => METHOD FOR SELECTING CANCER PATIENTS FOR WHOM COMBINATION THERAPY WITH RETINOID AND CANCER THERAPEUTIC AGENT IS EFFECTIVE, AND COMBINATION MEDICAMENT WITH RETINOID AND CANCER THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 18/010686 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537574 [patent_doc_number] => 20230242673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => ANTI-PCSK9 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/003121 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610907 [patent_doc_number] => 20230277637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => METHOD FOR THE TREATMENT OF A VIRAL INFECTION WITH HUMAN ALPHA-1 ANTITRYPSIN [patent_app_type] => utility [patent_app_number] => 17/999362 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999362 [rel_patent_id] =>[rel_patent_doc_number] =>)